Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of CER-001 in genetically diagnosed primary familial hypoalphalipoproteinemia
MOH_2017-03-01_000105Phase 3Completed
- Sponsor
- ABIONYX Pharma
- Start
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in familial hypoalphalipoproteinaemia (FHA) and atherosclerosis comparing CER-001 with Placebo (2 arms). Primary endpoint: Safety and efficacy on vessel wall cross-sectional area. Started Jul 2016; status: completed.
02
Drugs
CER-001
03
Conditions
familial hypoalphalipoproteinaemia (FHA)atherosclerosis
Beyond the preview
Go deeper on MOH_2017-03-01_000105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-01_000105.